Tadalafil and alpha-blockers can both lower systemic blood pressure through vasodilation. When the two drug classes are used together, their effects can add, which may produce clinically significant hypotension and symptoms such as dizziness or fainting in some patients.
The interaction cannot be summarized as either 'always contraindicated' or 'always safe.' Current U.S. CIALIS labeling treats the combination differently according to the indication: for erectile dysfunction, alpha-blocker stability and cautious initiation matter; for treatment of benign prostatic hyperplasia, tadalafil combined with an alpha-blocker is not recommended.
This page focuses specifically on that interaction and on why alpha-blockers should not be treated as one interchangeable group. Broader interaction categories belong on the tadalafil drug-interactions page, while general BPH treatment belongs on the tadalafil for BPH page.
The central interaction is pharmacodynamic rather than a simple change in tadalafil concentration. Both PDE5 inhibition and alpha-adrenergic blockade can reduce vascular tone, so blood pressure may fall further when the effects overlap.
Current labeling does not classify all alpha-blocker use as a formal tadalafil contraindication. Instead, it provides an ED-specific caution framework and separately states that tadalafil plus an alpha-blocker is not recommended for treating BPH.
That indication-specific distinction is the most important starting point for interpreting the combination.
| Context | Current label approach | Main concern |
|---|---|---|
| ED + patient already stable on alpha-blocker | Use caution; tadalafil is initiated at the lowest recommended dose | Additive blood-pressure lowering |
| Hemodynamic instability on alpha-blocker alone | Higher risk with addition of a PDE5 inhibitor | Symptomatic hypotension |
| Starting an alpha-blocker in a patient already on optimized PDE5 therapy | Begin alpha-blocker at its lowest dose and titrate cautiously | Further BP lowering during dose escalation |
| Tadalafil + alpha-blocker for BPH treatment | Not recommended | Blood-pressure lowering plus inadequately established combination efficacy |
| All alpha-blocker use | Not a blanket tadalafil contraindication | Depends on indication and hemodynamic context |
Tadalafil is a PDE5 inhibitor with mild systemic vasodilatory effects. Alpha-blockers reduce alpha-adrenergic signaling in vascular smooth muscle and can also lower vascular resistance and blood pressure.
When two vasodilators are combined, an additive hemodynamic effect can occur even if neither drug changes the other's plasma concentration. Current CIALIS labeling therefore describes the interaction primarily in terms of blood-pressure lowering rather than metabolic interference.
The same general principle applies to several other vasodilator interactions, but the alpha-blocker combination has its own detailed clinical pharmacology evidence.
| Drug class | Relevant action | Combined implication |
|---|---|---|
| Tadalafil | PDE5 inhibition with systemic vasodilatory potential | Can contribute to additional BP reduction |
| Alpha-blocker | Reduces alpha-adrenergic vascular tone | Can lower BP independently |
| Combination | Overlapping vasodilation | Possible symptomatic hypotension or fainting |
For erectile dysfunction, current labeling does not prohibit every tadalafil–alpha-blocker combination. A patient already receiving an alpha-blocker should be hemodynamically stable before tadalafil is introduced, and tadalafil should be initiated at the lowest recommended dose.
For treatment of BPH, the wording is different. Current CIALIS labeling states that the efficacy of coadministering tadalafil and an alpha-blocker for BPH has not been adequately studied and that, because of the potential for additive blood-pressure lowering, the combination is not recommended for BPH treatment.
That difference means an ED interaction rule should not be copied into a BPH answer without preserving the indication.
| Indication | Alpha-blocker + tadalafil framework |
|---|---|
| Erectile dysfunction | Possible under label-defined caution when alpha-blocker therapy is stable |
| BPH treatment | Combination not recommended |
| ED + BPH | Do not infer a combination regimen from the ED rule; indication and BPH labeling still matter |
Current CIALIS warnings state that patients should be stable on alpha-blocker therapy before a PDE5 inhibitor is initiated. Patients who already demonstrate hemodynamic instability on the alpha-blocker alone are considered at increased risk of symptomatic hypotension when a PDE5 inhibitor is added.
Stability is therefore a hemodynamic concept rather than simply a count of how many days a medicine has been taken. The labeling does not reduce the decision to a universal waiting period that applies to every alpha-blocker and every patient.
Broader cardiovascular suitability and hypotension precautions are covered on the tadalafil warnings page.
| Situation | Implication |
|---|---|
| Stable on alpha-blocker therapy | Required context before tadalafil initiation for ED |
| Hemodynamic instability on alpha-blocker alone | Higher risk of symptomatic hypotension with PDE5 inhibitor addition |
| Universal fixed waiting interval | Not the way current CIALIS labeling defines stability |
For ED, current CIALIS labeling states that tadalafil should be initiated at the lowest recommended dose when the patient is already stable on alpha-blocker therapy. This reflects the possibility that adding another vasodilatory drug can produce a larger blood-pressure response than either medicine alone.
The instruction should not be generalized into a personalized dose recommendation outside the prescribing context. Tadalafil dosing also depends on the indication, regimen, kidney or liver function and other interacting medicines.
The broader dose framework belongs on the tadalafil dosage page.
| ED context | Current-label principle |
|---|---|
| Alpha-blocker already established and stable | Tadalafil starts at the lowest recommended dose |
| Alpha-blocker not hemodynamically stable | Risk of symptomatic hypotension is greater |
| Exact individualized tadalafil selection | Requires the full clinical and prescribing context |
Current CIALIS labeling also addresses the interaction in the opposite direction. In a patient already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should begin at the lowest alpha-blocker dose.
The label notes that stepwise increases in the alpha-blocker dose may produce further blood-pressure lowering while a PDE5 inhibitor is being taken. This makes dose escalation another relevant part of the interaction rather than treating the combination as a fixed yes-or-no state.
The principle again reflects hemodynamic overlap rather than a metabolic interaction.
| Treatment change | Label consideration |
|---|---|
| Alpha-blocker added to optimized PDE5 therapy | Initiate alpha-blocker at its lowest dose |
| Alpha-blocker dose increased stepwise | May produce additional blood-pressure lowering |
| Underlying mechanism | Additive vasodilatory effect |
The safety of tadalafil and alpha-blocker coadministration is not determined by the two drug names alone. Current labeling specifically notes that intravascular volume depletion and other antihypertensive drugs can affect the safety of the combination.
A patient taking several blood-pressure-lowering medications or experiencing reduced circulating volume may therefore respond differently from a healthy volunteer in a controlled pharmacology study. That is one reason trial averages should not be treated as individual predictions.
Tadalafil's broader blood-pressure effects are discussed on the tadalafil and blood pressure page.
| Additional factor | Potential relevance |
|---|---|
| Intravascular volume depletion | May increase susceptibility to hypotension |
| Other antihypertensive drugs | Can add further blood-pressure lowering |
| Baseline hemodynamic instability | Raises concern before another vasodilator is added |
| Healthy-volunteer study result | Does not predict every patient's response |
Current CIALIS labeling reports six randomized, double-blind crossover clinical pharmacology studies evaluating tadalafil with alpha-blocker agents in healthy men. The studied drugs included doxazosin, tamsulosin and alfuzosin.
The hemodynamic findings were not identical across those agents, doses and study designs. Doxazosin studies produced more pronounced blood-pressure effects in several settings, whereas the studied tamsulosin regimens generally produced smaller placebo-subtracted mean changes and no syncope in the reported studies.
These differences should not be converted into a claim that one alpha-blocker combination is universally safe and another universally unsafe; the trials used specific doses, populations and timing conditions.
| Alpha-blocker studied | Examples of tadalafil regimen | High-level study pattern |
|---|---|---|
| Doxazosin | Tadalafil 20 mg single dose and tadalafil 5 mg daily regimens were studied | Some studies showed larger BP reductions, more outliers and symptomatic events |
| Tamsulosin | Tadalafil 10 or 20 mg single dose and tadalafil 5 mg daily were studied | Smaller mean BP differences in the reported studies; no syncope reported |
| Alfuzosin | Tadalafil 20 mg single dose studied | Modest mean BP changes in the reported healthy-volunteer study |
Three clinical pharmacology studies in current CIALIS labeling evaluated tadalafil with doxazosin. In the first study, 18 healthy subjects receiving doxazosin 8 mg daily were given tadalafil 20 mg or placebo; the placebo-subtracted mean maximal decrease in standing systolic blood pressure with tadalafil was 9.8 mm Hg.
That study also recorded more predefined blood-pressure outliers after tadalafil than placebo, and two potentially blood-pressure-related severe adverse events — vertigo and dizziness — were reported after tadalafil. No syncope occurred in that first study.
A second doxazosin study again found more blood-pressure outliers with tadalafil, including an episode of symptomatic hypotension. These results help explain why alpha-blocker interactions cannot be reduced to a class-wide assumption based on one more selective agent.
| Doxazosin evidence point | Current CIALIS label |
|---|---|
| Study 1 | Doxazosin 8 mg daily + tadalafil 20 mg single dose |
| Standing placebo-subtracted mean maximal SBP decrease | 9.8 mm Hg |
| Predefined BP outliers | More frequent following tadalafil than placebo |
| Potentially BP-related severe events | Vertigo and dizziness reported after tadalafil |
| Study 2 | Additional outliers and one symptomatic-hypotension event reported with tadalafil |
A third doxazosin study used a different design: healthy subjects received tadalafil 5 mg once daily or placebo, while doxazosin was introduced at 1 mg and titrated to 4 mg. Mean placebo-subtracted blood-pressure differences after doxazosin 4 mg were relatively small in that study.
However, two episodes of syncope occurred during the study: one after tadalafil 5 mg alone and another after tadalafil 5 mg was coadministered with doxazosin 4 mg. This illustrates why one average blood-pressure number does not capture the complete safety signal.
The different doxazosin studies also demonstrate why results cannot be pooled without preserving tadalafil dose, alpha-blocker dose, treatment sequence and study design.
| Study feature | Doxazosin Study 3 |
|---|---|
| Tadalafil regimen | 5 mg once daily |
| Doxazosin regimen | Started at 1 mg and titrated to 4 mg |
| Mean BP differences at 4 mg doxazosin | Relatively small in the reported comparisons |
| Syncope | One episode after tadalafil alone and one after tadalafil + doxazosin |
| Interpretive lesson | Mean BP change alone does not define all individual hemodynamic risk |
Tamsulosin is a more alpha-1A-selective blocker and produced a different pattern in the clinical pharmacology studies described in current CIALIS labeling. In one study, healthy subjects stabilized on tamsulosin 0.4 mg daily received tadalafil 10 mg, tadalafil 20 mg or placebo.
Placebo-subtracted mean maximal standing systolic blood-pressure reductions were 1.7 mm Hg with tadalafil 10 mg and 2.3 mm Hg with tadalafil 20 mg. No subject had standing systolic pressure below 85 mm Hg, no severe blood-pressure-related adverse event was reported and no syncope occurred.
These findings are reassuring within that specific study design, but they do not erase the label's class-level caution or justify treating tamsulosin as automatically safe with tadalafil in every clinical setting.
| Tamsulosin Study 1 feature | Result |
|---|---|
| Tamsulosin dose | 0.4 mg once daily |
| Tadalafil doses | 10 mg and 20 mg single doses |
| Standing mean maximal SBP difference — tadalafil 10 mg | 1.7 mm Hg vs placebo |
| Standing mean maximal SBP difference — tadalafil 20 mg | 2.3 mm Hg vs placebo |
| Standing SBP <85 mm Hg | None |
| Syncope | None reported |
A second tamsulosin study evaluated repeated tadalafil 5 mg once-daily dosing. Healthy subjects received tadalafil 5 mg or placebo for 14 days, and tamsulosin 0.4 mg daily was added during the final 7 days.
The reported placebo-subtracted mean maximal standing systolic blood-pressure differences were 0.9 mm Hg on the first day of tamsulosin and 1.2 mm Hg on day 7. No severe blood-pressure-related adverse events and no syncope were reported.
Again, these data describe a controlled healthy-volunteer setting rather than establishing a universal prediction for older patients with BPH, cardiovascular disease, volume depletion or multiple antihypertensive medications.
| Tamsulosin Study 2 feature | Result |
|---|---|
| Tadalafil | 5 mg once daily |
| Tamsulosin | 0.4 mg once daily during final 7 days |
| Standing SBP difference — Day 1 | 0.9 mm Hg vs placebo |
| Standing SBP difference — Day 7 | 1.2 mm Hg vs placebo |
| Severe BP-related adverse events | None reported |
| Syncope | None reported |
Current CIALIS labeling also describes a healthy-volunteer interaction study with alfuzosin. Participants stabilized on alfuzosin extended release 10 mg daily received tadalafil 20 mg or placebo.
The placebo-subtracted mean maximal decrease in standing systolic blood pressure was 4.4 mm Hg. One tadalafil-treated subject had a standing systolic blood pressure below 85 mm Hg, while no severe blood-pressure-related adverse events or syncope were reported.
The alfuzosin data further reinforce the point that alpha-blocker evidence is agent- and regimen-specific rather than interchangeable.
| Alfuzosin study feature | Result |
|---|---|
| Alfuzosin | 10 mg extended release once daily |
| Tadalafil | 20 mg single dose |
| Standing mean maximal SBP difference | 4.4 mm Hg vs placebo |
| Standing SBP <85 mm Hg | One tadalafil-treated subject |
| Severe BP-related adverse events / syncope | None reported |
The doxazosin, tamsulosin and alfuzosin studies differed in alpha-blocker selectivity, dose, tadalafil regimen, timing, sample size and whether treatment was given once or repeatedly. A direct numerical ranking across them would therefore ignore important design differences.
The studies are most useful for showing that alpha-blocker interactions are heterogeneous and that hemodynamic effects depend on more than the class name. They do not establish that one alpha-blocker can be declared universally 'safe with Cialis' while another is universally prohibited.
Clinical interpretation should preserve the specific agent, dose, indication and patient context.
| Why cross-study ranking is limited | Examples |
|---|---|
| Different alpha-blockers | Doxazosin, tamsulosin, alfuzosin |
| Different tadalafil regimens | 5 mg daily, 10 mg single dose, 20 mg single dose |
| Different alpha-blocker doses | Agent-specific doses and titration schedules |
| Different timing | Simultaneous or separated administration depending on study |
| Small healthy-volunteer samples | Not equivalent to all real-world BPH or ED populations |
The controlled tamsulosin studies showed relatively small mean blood-pressure differences and no syncope under the studied conditions. That evidence is relevant, but it does not convert the combination into an unrestricted recommendation.
Current CIALIS labeling still advises caution with alpha-blockers as a class and uses the same stability framework for ED. For BPH treatment, the tadalafil–alpha-blocker combination remains not recommended even though tamsulosin-specific pharmacology studies produced less pronounced average hemodynamic effects than some doxazosin studies.
This distinction prevents a favorable healthy-volunteer study from overriding indication-specific prescribing language.
| Statement | Accurate? |
|---|---|
| Tamsulosin studies showed relatively small average BP changes | Yes |
| Therefore tadalafil + tamsulosin is universally safe | No |
| Alpha-blocker stability still matters for ED | Yes |
| Tadalafil + an alpha-blocker is recommended for BPH treatment | No |
Current CIALIS warnings go beyond simply stating that alpha-blocker combination therapy is not recommended for BPH. They state that patients receiving an alpha-blocker for BPH should discontinue the alpha-blocker at least one day before starting once-daily CIALIS for BPH.
This is label-specific transition language for BPH treatment and should not be generalized into a self-directed medication-switching instruction. Alpha-blockers may also be prescribed for hypertension or other reasons, so the indication for the alpha-blocker must be known before the rule is interpreted.
The broader therapeutic role of tadalafil in urinary symptoms belongs on the tadalafil for BPH page.
| BPH label point | Interpretation |
|---|---|
| Tadalafil + alpha-blocker for BPH | Not recommended |
| Patient using alpha-blocker specifically for BPH before starting daily CIALIS for BPH | Current label states the alpha-blocker should be discontinued at least one day beforehand |
| Alpha-blocker used for another indication | Requires its own clinical context; do not apply the BPH transition wording blindly |
Tadalafil is labeled for patients with both erectile dysfunction and signs and symptoms of BPH, but that does not erase the alpha-blocker warning. The existence of a combined ED/BPH tadalafil indication is separate from whether an alpha-blocker should also remain part of the regimen.
This is an important cannibalization boundary: the present page owns the interaction question, while treatment selection for a person with both conditions belongs on the tadalafil for ED and BPH page.
A user should therefore not infer a three-part treatment strategy simply because tadalafil and an alpha-blocker can each be used in conditions involving urinary or sexual symptoms.
| Concept | Meaning |
|---|---|
| Tadalafil has an ED/BPH indication | Yes |
| That automatically validates tadalafil + alpha-blocker combination treatment for BPH | No |
| Interaction guidance still applies | Yes |
CIALIS patient information lists several examples of alpha-blockers, including tamsulosin, doxazosin, alfuzosin, terazosin, prazosin and silodosin, as well as combination products containing an alpha-blocker. The detailed tadalafil clinical pharmacology program, however, did not study every listed agent in the same way.
That distinction matters. Being named as an alpha-blocker in patient counseling does not mean a drug has the same tadalafil-specific study dataset as doxazosin, tamsulosin or alfuzosin.
Medication review should therefore identify the exact active ingredient rather than relying on the generic phrase 'prostate medication.'
| Alpha-blocker example in CIALIS patient information | Dedicated tadalafil clinical pharmacology study described in current label? |
|---|---|
| Doxazosin | Yes |
| Tamsulosin | Yes |
| Alfuzosin | Yes |
| Terazosin | Not described in the same dedicated interaction-study series |
| Prazosin | Not described in the same dedicated interaction-study series |
| Silodosin | Not described in the same dedicated interaction-study series |
The principal clinically important consequence of excessive additive vasodilation is symptomatic hypotension. Current CIALIS labeling specifically gives fainting as an example, while patient counseling warns that blood pressure can suddenly fall with certain alpha-blockers and that dizziness or fainting may occur.
Symptoms are important, but the absence of symptoms during a previous dose does not prove that every later combination will produce the same response. Changes in alpha-blocker dose, hydration or volume status and other antihypertensive drugs can change the hemodynamic context.
The interaction is therefore assessed prospectively rather than only after symptoms appear.
| Possible signal | Interaction context |
|---|---|
| Dizziness | May accompany blood-pressure lowering |
| Fainting / syncope | Potential manifestation of symptomatic hypotension |
| Prior symptom-free use | Does not guarantee identical response after dose or medication changes |
Both nitrates and alpha-blockers can contribute to tadalafil-related blood-pressure concerns, but the regulatory categories are fundamentally different. Organic nitrates are formal contraindications with tadalafil, whereas alpha-blockers use an indication-specific caution framework.
This means users should not generalize the nitrate rule to alpha-blockers, nor should they generalize the more flexible ED alpha-blocker framework to nitrates. Each drug class has its own evidence and label language.
The nitrate-specific contraindication and timing evidence are covered on the tadalafil and nitrates page.
| Interaction | Formal category |
|---|---|
| Tadalafil + organic nitrate | Contraindicated |
| Tadalafil + alpha-blocker for ED | Caution with hemodynamic-stability framework |
| Tadalafil + alpha-blocker for BPH | Not recommended |
The alpha-blocker interaction is often oversimplified into one of two incorrect claims: either that tadalafil can never be used with any alpha-blocker, or that tamsulosin study results prove the entire class is safe. Current labeling supports neither extreme.
A second mistake is ignoring the indication. ED guidance and BPH guidance are intentionally different, and the BPH combination is not recommended even though tadalafil and alpha-blockers can each independently be used in men with urinary symptoms.
Finally, study averages should not be treated as personalized blood-pressure forecasts because individual susceptibility and concomitant treatment can alter the response.
| Misunderstanding | Correct interpretation |
|---|---|
| All alpha-blockers are contraindicated with tadalafil | No |
| Tamsulosin has no tadalafil interaction | No; additive hypotension remains a class concern |
| ED and BPH use the same combination rule | No |
| A small mean BP change guarantees an individual will not become hypotensive | No |
| Different alpha-blocker studies can be directly ranked without qualification | No |
The most useful interaction review identifies the exact alpha-blocker, the reason it is being used and whether treatment is hemodynamically stable. Those questions matter more than simply seeing the phrase 'alpha-blocker' on a medication list.
Other blood-pressure-lowering drugs and volume status also belong in the review because they can change the combined hemodynamic effect.
| Check | Question |
|---|---|
| Exact alpha-blocker | Is the drug tamsulosin, doxazosin, alfuzosin or another alpha-blocker? |
| Indication | Is the alpha-blocker being used for BPH, hypertension or another reason? |
| Hemodynamic stability | Is blood pressure stable on the alpha-blocker before tadalafil is considered for ED? |
| Treatment sequence | Which drug is already established and which is being introduced or titrated? |
| Other antihypertensives | Could additional blood-pressure-lowering medicines amplify the effect? |
| Volume status | Could intravascular volume depletion increase susceptibility? |
| BPH combination | Is tadalafil plus an alpha-blocker being proposed specifically to treat BPH, where current labeling says the combination is not recommended? |
Tadalafil and alpha-blockers are both vasodilators, so concomitant use can produce additive blood-pressure lowering and symptomatic hypotension. Alpha-blocker use is not a blanket formal tadalafil contraindication, but the label requires careful interpretation of hemodynamic stability, treatment sequence and other blood-pressure-lowering factors.
For ED, current labeling allows an interaction-management framework: a patient taking an alpha-blocker should be stable before tadalafil is introduced, and tadalafil begins at the lowest recommended dose. For BPH treatment, tadalafil combined with an alpha-blocker is not recommended because combination efficacy has not been adequately established and additive blood-pressure lowering is a concern.
Clinical pharmacology studies also show why the class should not be treated as uniform. Doxazosin, tamsulosin and alfuzosin produced different hemodynamic patterns under different study conditions, so one agent's results should not be generalized to every alpha-blocker or every patient.
Alpha-blockers are not a blanket formal contraindication with tadalafil, but both drug classes lower blood pressure. For ED, current labeling uses a caution framework based on alpha-blocker stability and low-dose initiation; for BPH treatment, tadalafil plus an alpha-blocker is not recommended.
Both tadalafil and alpha-blockers have vasodilatory blood-pressure-lowering effects. Their combined pharmacodynamic effects can produce additional blood-pressure reduction and, in some patients, symptomatic hypotension.
Tamsulosin is not a blanket contraindication with Cialis, and controlled interaction studies have been performed. However, current CIALIS labeling still advises caution with alpha-blockers, and the appropriate framework differs between ED and BPH treatment.
Yes. Flomax contains tamsulosin, an alpha-1A adrenergic blocker. The combination has been studied with tadalafil, but additive blood-pressure lowering remains the relevant interaction concern.
In healthy-volunteer studies described in current CIALIS labeling, tamsulosin 0.4 mg with tadalafil produced relatively small placebo-subtracted mean systolic blood-pressure changes, and no syncope was reported. Those findings apply to the studied regimens and do not establish universal safety for every patient.
Yes. Current CIALIS labeling describes several doxazosin studies in which tadalafil produced more substantial hemodynamic effects in some settings, including more blood-pressure outliers and symptomatic events.
Some doxazosin studies showed larger blood-pressure effects than the tamsulosin studies, but the trials differed in drug selectivity, dose, tadalafil regimen, timing and design. They should not be treated as a direct universal ranking of alpha-blocker safety.
Yes. Alfuzosin was evaluated in a controlled healthy-volunteer study with tadalafil 20 mg. The reported mean blood-pressure effect was modest, but the general alpha-blocker caution still applies.
Not as a blanket rule. Unlike organic nitrates, alpha-blockers are not listed as a universal formal tadalafil contraindication. Current labeling instead provides ED-specific caution and states that the combination is not recommended for treatment of BPH.
Patients who are hemodynamically unstable on alpha-blocker therapy alone are at greater risk of symptomatic hypotension when another vasodilator such as a PDE5 inhibitor is added. Current labeling therefore requires stability before tadalafil initiation in this ED context.
In this labeling context, stability refers to tolerating the alpha-blocker without clinically important blood-pressure instability. Current CIALIS labeling does not define it as one universal number of days that applies to every alpha-blocker and every patient.
The label uses this approach because both treatments can lower blood pressure. Starting tadalafil at the lowest recommended dose reduces the initial vasodilatory burden when it is added to stable alpha-blocker therapy.
Current CIALIS labeling states that in patients already taking an optimized PDE5-inhibitor dose, alpha-blocker therapy should begin at the lowest alpha-blocker dose. Stepwise alpha-blocker dose increases may cause further blood-pressure lowering.
Current CIALIS labeling states that tadalafil plus an alpha-blocker is not recommended for treatment of BPH because combination efficacy has not been adequately studied and additive blood-pressure lowering is a concern.
Current CIALIS labeling states that patients receiving an alpha-blocker for BPH should discontinue that alpha-blocker at least one day before starting once-daily CIALIS for treatment of BPH. This is label-specific clinician-directed treatment guidance, not a universal self-directed switching rule.
Tadalafil is labeled for patients with both ED and BPH, but that does not remove the alpha-blocker interaction guidance. The presence of both conditions should not be interpreted as automatic approval of tadalafil plus alpha-blocker combination treatment.
Yes. Additive blood-pressure lowering can produce symptomatic hypotension, and current patient counseling specifically warns that dizziness or fainting can occur when Cialis is combined with certain alpha-blockers.
Yes. Current labeling specifically notes that the safety of PDE5 inhibitor and alpha-blocker coadministration can be affected by other antihypertensive medicines and by intravascular volume depletion.
No. Alpha-blockers differ in receptor selectivity, dose and hemodynamic profile, and tadalafil interaction studies with doxazosin, tamsulosin and alfuzosin produced different patterns. Those studies should not be generalized across the entire class without qualification.
No. Both can involve blood-pressure lowering, but organic nitrates are formally contraindicated with tadalafil. Alpha-blockers instead have a caution framework for ED and a not-recommended combination framework for BPH treatment.